A growing body of data suggests that monoclonal antibodies against PD-1/PD-L1, a type of ICI, can induce durable clinical responses in some patients with metastatic TNBC and may also have meaningful clinical activity in patients with rare ER+ HER-2- BC (64). Here, ERBB2 is linked to breast cancer.